It looks like you are using an older version of Internet Explorer which is not supported. We advise that you update your browser to the latest version of Microsoft Edge, or
consider using other browsers such as Chrome, Firefox or Safari.
You may have questions about your patient's treatment journey. For potential answers, look through our FAQs below. And remember, you can always call the OmniSource® hub on 877.456.6794 (Monday – Friday, 8 AM – 8 PM ET).
Omnitrope is a recombinant human growth hormone indicated for:
Pediatric: Treatment of children with growth failure due to growth hormone deficiency (GHD), Prader-Willi Syndrome, Small for Gestational Age, Turner Syndrome, and Idiopathic Short Stature
Adult: Treatment of adults with either adult onset or childhood onset GHD
The primary action of somatropin is linear growth (eg, increase in height), including skeletal and cell growth. Growth hormone also influences protein, carbohydrate, lipid, mineral, and connective tissue metabolism.1
Omnitrope is supplied in prefilled liquid cartridges for use with the Omnitrope Pen or a vial for reconstitution.
Instruct your patient - or their caregiver - to take the missed dose as soon as possible. If the patient realizes a dose was missed and it is almost time for the next scheduled dose, tell your patient - or their caregiver - to not use extra medicine to make up for the missed dose.
Store Omnitrope refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze. Omnitrope is light sensitive and should be stored in the carton. After first use of a cartridge, the cartridge should remain in the pen and kept in a refrigerator at 2°C to 8°C (36°F to 46°F) for a maximum of 28 days. After reconstitution of a vial, the contents of the vial must be used within 3 weeks. After the first injection, the vial should be stored in the carton in a refrigerator at 2°C to 8°C (36°F to 46°F).1
Omnitrope is contraindicated in the following1:
Common adverse reactions reported in adult and pediatric patients taking somatropin include injection site reactions/rashes, lipoatrophy, and headaches. Additional common adverse reactions include edema, arthralgia, myalgia, carpal tunnel syndrome, paresthesia, and hypothyroidism.
Omnitrope is given as a weekly dose that should be divided over 6 or 7 days of subcutaneous injections. Omnitrope offers a liquid-formulation pen and a lyophilized powder: Omnitrope® Pen 5, Omnitrope® Pen 10, and Omnitrope® 5.8 mg Vial. Multiple options for administration allow for a more personalized and broader injection range for you and your patients.1
Omnitrope is injected just below the skin. Recommended areas include the thigh, stomach, or buttocks. Advise on how to rotate injection spots to avoid tissue atrophy (damage to local tissue).
OmniSource is a support program for Omnitrope patients and caregivers. The professionals at OmniSource are skilled at answering questions about patient services, guiding through the insurance process, and providing helpful Omnitrope materials. They also can arrange for a Nurse Trainer to provide injection training.
An OCM is skilled at getting the answers needed, guiding through the onboarding process, and providing personalized service for the growth hormone journey.
During the Omnitrope onboarding process, the OCM will call to make an introduction and welcome the patient to the OmniSource Program. He or she will also confirm contact information and help identify the resources OmniSource offers to answer nonmedical questions and needs.
Your patient should expect a call from an OCM with important information about beginning treatment. The OCM will help to provide growth hormone product and supplies, including shipment of the Starter Kit and pen device, if applicable.
OmniSource is here for support. Call 877.456.6794 (Monday – Friday, 8 AM – 8 PM ET).
A Nurse Trainer is a professional who can provide in-home training on how to properly use the Omnitrope Pen or vial and syringe. It’s a free service, and open to any family member or authorized caregiver. Please note that in order to receive injection training from a Nurse Trainer, a doctor must order it on the Statement of Medical Necessity at the patient's request.
If a refresher or additional training is needed, a Nurse Trainer is available. Please call an Omnitrope Case Manager for more information."
Your patient can contact an Omnitrope Case Manager with questions about insurance — he or she will be glad to help. Your patient should have an insurance card handy when he or she calls 877.456.6794 (Monday – Friday, 8 AM – 8 PM ET).
Eligible* patients may receive a $5,000 upfront annual benefit and pay no more than $0 for their monthly co-pay for up to 12 months.
*Omnitrope Co-Pay Savings Program Eligibility:
The Omnitrope Co-Pay Savings Program provides up to $5,000 in annual co-pay support for Omnitrope prescriptions. With the Omnitrope Co-Pay Savings Program, eligible patients may pay $0 for their co-pay. Eligible patients who are commercially insured may receive co-pay support in the amount of up to $5,000 annually, and patients who are uninsured may receive co-pay support in the amount of up to $417 monthly, with an annual cap of $5,000. Prescription must be for an approved indication. This program is not health insurance. Patients are not eligible if prescriptions are paid, in whole or in part, by any state or federally funded programs, including but not limited to Medicare (including Part D, even in the coverage gap) or Medicaid, Medigap, VA, DoD, or TRICARE, or private indemnity, or HMO insurance plans that reimburse you for the entire cost of your prescription drugs, or where prohibited by law. Patients can participate for a maximum of 12 months. Eligible patients must have a first use of the program by December 31st of the current year. Omnitrope Co-Pay Savings Program has no cash value. Omnitrope Co-Pay Savings Program may not be combined with any other rebate, coupon, or offer. Sandoz reserves the right to rescind, revoke, or amend this offer without further notice.
Instruct your patient to contact an Omnitrope Case Manager at 877.456.6794 (Monday – Friday, 8 AM – 8 PM ET).
Personalized support services to help your patients each step of the way.
Savings support for the journey ahead - eligible patients may pay as little as $0 for their Co-Pay.*
Personalized support, each step of the way. Click here to enroll your patient.
Omnitrope® is a recombinant human growth hormone indicated for:
Please see full Prescribing Information for Omnitrope.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
To report SUSPECTED ADVERSE REACTIONS, contact Sandoz Inc. at 1-800-525-8747 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch